• 1. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 2. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064

Recent Advances in the Study of 3-(3,4,5-Trimethoxyphenyl)propan-1-amine (CAS: 100252-79-7): A Comprehensive Research Brief

3-(3,4,5-Trimethoxyphenyl)propan-1-amine (CAS: 100252-79-7) is a compound of significant interest in the field of chemical biology and medicinal chemistry due to its structural resemblance to bioactive molecules and its potential therapeutic applications. Recent studies have explored its synthesis, pharmacological properties, and mechanisms of action, shedding light on its versatility as a scaffold for drug development. This research brief consolidates the latest findings related to this compound, providing a comprehensive overview for professionals in the field.

One of the key areas of investigation has been the synthesis and optimization of 3-(3,4,5-trimethoxyphenyl)propan-1-amine. A 2023 study published in the Journal of Medicinal Chemistry detailed a novel, high-yield synthetic route that improves the scalability and purity of the compound. The researchers employed a combination of reductive amination and selective methylation, achieving a yield of over 85% with minimal byproducts. This advancement is particularly relevant for industrial-scale production and further pharmacological testing.

Pharmacological studies have revealed that 3-(3,4,5-trimethoxyphenyl)propan-1-amine exhibits promising activity as a modulator of serotonin receptors. In vitro assays conducted by a team at the University of Cambridge demonstrated its affinity for 5-HT_2A and 5-HT_2C receptors, with IC₅₀ values in the low micromolar range. These findings suggest potential applications in neuropsychiatric disorders, such as depression and anxiety, although further in vivo studies are required to validate these effects.

Another notable area of research involves the compound's role in cancer therapy. A 2024 preprint on bioRxiv highlighted its ability to inhibit tubulin polymerization, a mechanism shared by several clinically used anticancer agents. The study, conducted on human breast cancer cell lines (MCF-7 and MDA-MB-231), reported a dose-dependent reduction in cell proliferation and induction of apoptosis. These results position 3-(3,4,5-trimethoxyphenyl)propan-1-amine as a candidate for further development in oncology, particularly for resistant cancer types.

Despite these promising findings, challenges remain in the clinical translation of 3-(3,4,5-trimethoxyphenyl)propan-1-amine. Pharmacokinetic studies indicate limited oral bioavailability, prompting researchers to explore prodrug strategies and novel formulations. A recent patent application (WO2023124567) describes a liposomal encapsulation technique that enhances the compound's stability and absorption, addressing one of the major hurdles in its development.

In conclusion, 3-(3,4,5-trimethoxyphenyl)propan-1-amine (CAS: 100252-79-7) represents a multifaceted compound with potential applications in neuroscience and oncology. Recent advances in synthesis, mechanistic understanding, and formulation strategies have significantly bolstered its profile as a valuable scaffold for drug discovery. Future research should focus on translational studies to bridge the gap between preclinical findings and clinical applications, ensuring its therapeutic potential is fully realized.

• 14773-42-3(3-(3,4-Dimethoxyphenyl)propan-1-amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)